Zymo Research, Irvine, Calif, was granted the CE IVD Mark for its Quick SARS-CoV-2 rRT-PCR Kit, a real-time reverse transcription PCR (rRT-PCR) test used for the qualitative detection of nucleic acids from SARS-CoV-2 in upper and lower respiratory specimens. The test has been previously authorized by the FDA under an emergency use authorization. This kit features a limit of detection as low as 15 GEC per reaction (250 GEC/ml of sample) and a robust control system and includes ready-to-use reaction mixtures to reduce hands-on time and eliminate human errors during the set-up process. In addition, the test is fast and results are generated in less than 1.5 hours. “Receiving the CE IVD Mark for our Quick SARS-CoV-2 rRT-PCR Kit means we can better support covid-19 testing on a global level, something that Zymo Research has been deeply committed to since the start of the pandemic,” says Paolo Piatti, PhD, senior scientist at Zymo Research. For more information, visit Zymo Research. Featured image: Zymo Research’s Quick SARS-CoV-2 rRT-PCR Kit is a real-time reverse transcription PCR (rRT-PCR) test used for the qualitative detection of nucleic acids from SARS-CoV-2 in upper and lower respiratory specimens. (courtesy Zymo Research)